TRANSFORMING CARE
IN ANCA-ASSOCIATED VASCULITIS

TAVNEOS has received European Commission approval and will receive marketing authorization in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.

TAVNEOS, a novel therapy for GPA/MPA that selectively targets
C5aR to achieve and sustain remission while reducing GC use^1-3

TAVNEOS, in combination with rituximab or cyclophosphamide, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).¹

TAVNEOS should be initiated and monitored by healthcare professionals experienced in the diagnosis and treatment of GPA or MPA¹

References

1. TAVNEOS SmPC January 2022. 2. Jayne D, et al. N Engl J Med 2021;384(7):599–609. 3. Bekker P, et al. PLoS One 2016;11(10):e0164646.

TRANSFORMING CAREIN ANCA-ASSOCIATED VASCULITIS

TAVNEOS has received European Commission approval and will receive marketing authorization in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.

TAVNEOS, a novel therapy for GPA/MPA that selectively targets C5aR to achieve and sustain remission while reducing GC use1-3

Help us guide you to the right place

I am a health care professional

I am not a health care professional

Help us guide you to the right place

I am a health

care professional

Help us guide you to the right place

I am not a health

care professional

Back to options

Back to options

TRANSFORMING CARE
IN ANCA-ASSOCIATED VASCULITIS

TAVNEOS, a novel therapy for GPA/MPA that selectively targets
C5aR to achieve and sustain remission while reducing GC use^1-3